Fig. 6

a TC, b HDL, c LDL, and d TG CFB with DTG versus comparators. RE model. *Indicates treatment comparisons are significantly different. ATV/r, ritonavir-boosted atazanavir; BIC, bictegravir; CFB, change from baseline; Crl, credible interval; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; EFV, efavirenz; EVG/c, cobicistat-boosted elvitegravir; HDL, high-density lipoprotein; INSTIs, integrase strand inhibitors; LDL, low-density lipoprotein; LPV/r, lopinavir-boosted ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; OR, odds ratio; PIs, protease inhibitors; RAL, raltegravir; RE, random effect; RPV, rilpivirine; TC, total cholesterol; TG, triglycerides